Instructions for Authors

Submit-your-article-300x104

Instructions for Authors

ISSN 2476-0994

 

Our Journal makes a plagiarism checker by a certificate program.

 

International Journal of Medical Device and Adjuvant Treatments publishes Editorials, Reviews, Original articles/Research articles, Brief communication, Short reports, Case reports, and Scientific Correspondence on several aspects related to the development and use of medical devices, dietary supplements and/or other therapies considered as adjuvants of the traditional medical approach.

Several topics will be considered: basic research, prevention, public health, pharmacology and pharmacogenomics aspects, treatments, innovative aspects regarding diagnosis, pathology, preclinical and clinical-experimental studies.

International Journal of Medical Device and Adjuvant Treatments is particularly interested in therapies and diagnostics, including all aspects of translation medicine from bench to bedside: identification of novel therapeutic targets, epidemiology, clinical trials, drug safety, and meta-analyses. International Journal of Medical Device and Adjuvant Treatments does not accept for the publication “data not shown” or “unpublished data”.

 

Original Articles

Format guide:
• Word limit: 3500 words (excluding the abstract and references).
• Key words (5-8 key words)
• References: 50
• Abstract: 300 words or less (Background, Methods, Results and Conclusions).
• Tables/Figures: Do not repeat the data extensively in tables or figures.

 

Brief Communication

Format guide:
• Word limit: 1700 words (excluding the abstract and references).
• References: 10-20.
• Abstract: Up to 75 words, unstructured
• Tables/Figures: 1 table and 2 figure.

 

Review Articles

Reviews should include systematic revision of the literature concerning the treated topics and preferably meta-analyses, original illustration and tables.

Format guide:
• Word limit: 4000 words (excluding the abstract and references).
• Key points should be reported on the title page in 50-words or less.
• References: unlimited.
• Abstract: Up to 200 words, unstructured.
• Tables/Figures: as necessary

Editorials

Editorials are related to articles published in IJMDAT and are usually invited.

Format guide:
• Word limit: 1400 words.
• Tables/Figures: A maximum of 1 figure or table.
• References: 15 or less.

 

Letter to Editor

Letters are restricted to the discussion of papers already published in IJMDAT.

Format guide:

  • Word limit: 300 words.
    • Tables/Figures: A maximum of 1 figure or table.
    • References: 10 or less

 

Short Reports and Case Reports

They will be considered for publication only if of particular interest.

Format guide:

  • Word limit: 1100
  • Abstract must not exceed 200 words.

 

Manuscript Submissions

Authors should submit manuscripts, including supporting documents and figures to International Journal of Medical Device and Adjuvant Treatments. Please read and apply the loading instructions given at this site, noting that all information entered during the submission process related to the manuscript should also be included, and be identical to the final submitted version of the manuscript. please see full details under “Presentation of Manuscripts”. Papers must be submitted exclusively to the Journal, and are accepted on the understanding that they have not been, and will not be, published elsewhere. The correspondence for each article must be followed only by the corresponding author. The submission process requires a full declaration of personal interests of all Authors, and funding interests; these details should also be included in the text of the manuscript (see below).

Please note that the journal employs a plagiarism detection system. By submitting your manuscript to the journal you accept that your manuscript may be screened for plagiarism against previously published work.

Supporting Documents

Upon submission all manuscripts should include the following documents:

Cover Letter

The cover letter must include contact information [e-mail, addresses, telephone and fax numbers] for all authors. A corresponding and an alternate author who can be contacted if the corresponding author is unavailable, must be selected.

The letter should state that all authors have contributed, read and approved the manuscript, and also that the manuscript has not been previously published nor is not being considered for publication elsewhere. The names and contact information of 3 potential unbiased reviewers must be submitted. The names of individuals whom they do not want to review their manuscript can be remarked.

Authorship

Authors must fulfil the following criteria:

  • He/she must have made a substantial contribution to research design, or to the acquisition, analysis or interpretation of data;
  • He/she must have drafted the paper or revised it critically;
  • He/she must have given approval of the submitted and final versions

Copyright Transfer Agreement: All IJMDAT Authors will be required to sign a Copyright Transfer Agreement (click to download PDF) for all papers accepted for publication. Signature of the CTA is a condition of publication and papers will not be passed to the publisher for production unless a signed form has been received. After submission, Authors will retain the right to publish their paper in various media/circumstances. To assist Authors, an appropriate CTA form will be supplied by the editorial office. The original completed Copyright Transfer Agreement must be signed by the corresponding Author and sent by e-mail to IJMDAT. If a paper is accepted for publication, and this form has not been received, there will be a delay in the edited paper appearing in the forthcoming section on the IJMDAT website. The Editors retain the usual right to modify the style and length of a contribution (major changes being agreed with the corresponding Author) and to decide the time of publication.

Permissions

To reproduce any third party material, such as figures or tables, authors must request, obtain and show permission from the copyright holder.

A statement indicating that permission has been obtained must be included in the relevant legend/footnote.

PRESENTATION OF MANUSCRIPTS

General Information:

The manuscript should be typed with a wide margin. Authors should retain one copy of all material, as the Editors cannot accept responsibility for loss of, or damage to, a manuscript.

Pages should be numbered consecutively in Arabic numerals, but tables, footnotes, figure legends (including magnifications), acknowledgments, and declaration of interests must be submitted on separate sheets.

Abbreviations should be defined at the first use and should be kept to a minimum.

Language editing pre-submission: If English is not your first language, language editing is required before submission to ensure that the academic content of your paper is fully understood by journal editors and reviewers. Several editing companies offer such a services.

References should be numbered in the order in which they are first mentioned in the text, and should be identified in the text, tables, and legends by Arabic numbers in superscript. List all the Authors. The form of references adopted by the US National Library of Medicine and used in Index Medicus applies. References must be verified by the Authors against the original documents.

Authors who want to publish on our Journal must follow the guidelines on Good Publication Practice: COPE https://publicationethics.org/resources/guidelines and PERK http://jp.elsevier.com/_old/editors/perk. These guidelines aim to ensure that articles are published in a responsible and ethical manner.

Title page:

The Authors’ names, appointments and work address at the relevant time, plus the full contact details of the Corresponding Author including their current e-mail address must be reported.

A full and a short running title

Key words for indexing purposes (5-10).

Abstract:

Original article 300 words (Background, Methods, Results and Conclusions).

Brief communication 75 words, unstructured

Review 200 words, unstructured

Manuscript:

The paper should then proceed conventionally:

Introduction

Materials and Methods

Results

Discussion

Conclusions

References

Complete all the references as follow: list all the authors, year without month of publication, delete the number of the single issue after the volume’s number, name of the journal: write the international acronyms without any punctuation; you must put a space after semicolon and colon; moreover, initial and final pages must be entirely reported (NO 2014;2014:907-15, YES 2014; 2014: 907-915). Delete the PMID and DOI number when you have the data aforementioned.

(NO) Example 1: NAINAN OV, XIA G, VAUGHAN G, MARGOLIS HS. Diagnosis of hepatitis A virus infection: A molecular approach. Clinical Microbiology Reviews 2006:19:63-79.

(YES) Example 1: Nainan OV, Xia G, Vaughan G, Margolis HS. Diagnosis of hepatitis A virus infection: a molecular approach. Clin Microbiol Rev 2006; 19: 63-79.

(NO) Ahmad M., Esmeiran H., Alafafsheh A., Al-Ghabeesh S., Al-Hamdan Z. Beliefs and preferred communication channels toward patients with cancer in Jordan. WCRJ 2016;3(3):e753

(YES) Ahmad M, Esmeiran H, Alafafsheh A, Al-Ghabeesh S, Al-Hamdan Z. Beliefs and preferred communication channels toward patients with cancer in Jordan. WCRJ 2016; 3: e753.

See also other published articles on our website.

 

Illustrations

Figure legends should be included in the main text of the manuscript and not form part of the figures. For production purposes, it is best if you can supply figures in TIFF format; however, it is also possible to use Illustrator or Photoshop software saved in the ‘.eps’, ‘.tif’ or ‘.jpg’ format. If you are unable to provide these specified formats, please provide the figures in as many different file formats as soon as possible.

The figure resolution/specification for various types of original figures, at their final size, should be as follows: Line art – Minimum 600 dpi, measuring preferably 13 by 18 cm and no more than 20 by 25 cm in size. Halftone (i.e. both B/W and Colour photographs) – Minimum 300 dpi, measuring preferably 13 by 18 cm and no more than 20 by 25 cm in size. Line and tone (line art and halftone combined) – Minimum 600 dpi, measuring preferably 13 by 18 cm and no more than 20 by 25 cm in size.

For line figures, the lines should be solid, the text in a standard font and not blurred, and the overall image should be sharp and clear. Avoid using tints if possible; if they are essential to the understanding of the figure, try to make them coarse. As a guide, if the electronic files are viewed at 400% on the computer screen and they look blurred or pixellated in any way then they will NOT be of sufficient quality for printing.

Figure and table legends must be able to stand alone in the text and thus full descriptive legends for all figures and tables should be supplied.

 

Units and Abbreviations

All measurements should be in SI units with the exception of haemoglobin (g/dL) and blood pressure (mmHg). Original observations recorded in other units should be stated, together with the appropriate conversion factors. Standard abbreviations, without punctuation, are used. Units, Symbols and Abbreviations (1988) published by the Royal Society of Medicine, and SI: The International System of Units (1982) from HMSO both provide useful guides. Abbreviations, used sparingly, should follow the first full spelling, in parentheses. A list of abbreviations at the beginning of the article is accepted only if they are more than 8.

 

Drug Names

Generic names should, in general, be used. If an Author desires, brand names may be inserted in parentheses. Drug names are spelled out according to the European Pharmacopoeia, but the American spelling should be used after the first use of a drug name.

 

Statistics

Methods should be referenced. Two-tailed significance tests should be used unless explicitly stated. Controls should be described as completely as experimental subjects. Measures of location should be accompanied by measures of variability (e.g. mean and confidence intervals) as well as conventional probability values. Clinical trial reports should include the power of the study design.

 

Ethics, Institutional Review Boards and Informed Consent

Submitted clinical studies must include a reference to the appropriate Ethics Committee / Institutional Review Board (IRB) and have an appropriate Consent Form approved by the Ethics Committee / IRB before enrollment of the research subjects in the reported study. Appropriate review process and approval should be also documented for all pre-clinical experimental studies submitted. When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should be asked to indicate whether the institutional and national guide for the care and use of laboratory animals was followed. Should any questionable approval process emerge, the Editors reserve the right to reject any submitted paper.

Clinical trials

All clinical trials submitted to International Journal of Medical Device and Adjuvant Treatments for consideration of publication must be registered.

For reporting Clinical Trials Conducted by Pharmaceutical Companies, please ensure that clinical trials sponsored by pharmaceutical companies follow the guidelines on Good Publication Practice: http://www.gpp-guidelines.org.

The International Committee of Medical Journal Editors (ICMJE) defines a clinical trial as “any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials), are exempt.”

These guidelines aim to ensure that such trials are published in a responsible and ethical manner. The guidelines cover companies’ responsibility to endeavour to publish results of all studies, companies’ relations with investigators, measures to prevent redundant or premature publication, methods to improve trial identification, and the role of professional medical writers. When submitting your manuscript, please include the unique trial number and the name of the registry (e.g.,ClinicalTrials.gov or ISRCTN) at the end of the abstract and in your cover letter.

Plagiarism or other types of unethical publication practice

About plagiarism or other types of unethical publication practice, we follow the COPE (https://publicationethics.org/resources/guidelines) and PERK (http://www.elsevier.com/editors/perk) guidelines.

On a practical level, the first thing we do is conduct an early investigation using our anti‐plagiarism software. Our Journal makes a plagiarism checker by a certificate program on all the articles. Also, articles that are related to the suspected case of plagiarism or other unethical practice are checked accuracy by either the reviewer feedback and observations or the Editors own observations. Our anti‐plagiarism software, however, will not identify “salami slicing”. So it is imperative that each case is looked at individually and, therefore, we do not advocate the use of one statement of actions to penalize the offender. Each case is considered separately and, as editors, we will need to decide if it is a deliberate action on the part of the author or it is due to lack of understanding of the requirements of ethical writing. This can happen for new authors or some authors where translation to English is often difficult. An example of this is where there are no words/phrases in that language that translate into English, and a developing practice that we noted is the ‘borrowing’ of words, phrases or often sentences that are considered appropriate for what authors mean to say.

IJMDAT disapproves any kind of malpractice and unethical practice.

Financial support

All funding sources for the study should be reported in a separate section entitled “Funding”. This should appear before the “Acknowledgment” section.

Sources of financial support during the last two years must be acknowledged. Please read the following statements, adding those sections which are relevant at the end of your submitted manuscript under a heading ‘Statement of Interests’.

  1. Authors’ declaration of personal interests: (i) [Name of individual] has served as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. (ii) [Name of individual] is an employee of [name of organization]. (iii) [Name of individual] owns stocks and shares in [name of organization]. (iv) [Name of individual] owns patent [patent identification and brief description].
  2. Declaration of funding interests: (i) This study was funded [in part or in full] by [insert name of funding organization], grant number [insert grant or other identification number]. (ii) The [writing or preparation] of this paper was funded in part by [insert name of funding organization]. (iii) Initial data analyses were undertaken by [name of individuals if not listed as Authors] who are employees of [name company] and received funding from [insert name of funding organization]. (iv) Writing support was provided by [insert name of individual(s)] of [name company] and funded by [insert name of funding organization].

 

 

Acknowledgments

Any assistance in preparing the manuscript should be stated. Personal acknowledgment should precede those of institutions of agencies.

Authorship

Authors must fulfill the following criteria:

  • He/she must have made a substantial contribution to research design, or to the acquisition, analysis or interpretation of data;
  • He/she must have drafted the paper or revised it critically;
  • He/she must have given approval of the submitted and final versions

 

Conflicts of Interest (COI)

At the time of submission, IJMDAT policy requires that authors reveal any COI, including financial interests or connections, direct or indirect, or any other situations that could raise questions of bias in either the reported work or the conclusions, implications, or opinions stated. Disclosed potential COIs should include any relevant commercial or other source of funding for either author(s), or the sponsoring institution, the associated department(s) or organization(s). When considering whether you should declare a COI please consider the following question: Is there any arrangement that would embarrass you or any of your co-authors did not declare and that would emerge after publication and you had not declared it?

As an integral part of the online submission process, Corresponding authors are required to confirm whether they or their co-authors have any conflicts of interest to declare, and to provide details of these. If the Corresponding author is unable to confirm this information on behalf of all co-authors, the authors in question will then be required to submit a completed COI form to the Editorial Office. It is the Corresponding author’s responsibility to ensure that all authors adhere to this policy.

If the manuscript is published, COI information will be communicated in a statement within the published work.

COI in Industry Sponsored Research

Authors whose manuscripts are submitted for publication must declare all relevant sources of funding in support of the preparation of a manuscript. IJMDAT requires full disclosure of financial support as to whether it is from the tobacco industry, the pharmaceutical or any other industry, government agencies, or any other source. This information should be included in the Acknowledgements section of the manuscript.
Authors are required to specify sources of funding for the study and to indicate whether or not the text was reviewed by the sponsor prior to submission, i.e., whether the study was written with full investigator access to all relevant data and whether the sponsor exerted editorial influence over the written text. This information should be included in the cover letter. In addition to disclosure of direct financial support to the authors or their laboratory and prior sponsor-review of the paper, submitting authors are asked to disclose all relevant consultancies within the 12 months prior to submission, since the views expressed in the contribution could be influenced by the opinions they have expressed privately as consultants. This information should be included in the Acknowledgments section of the manuscript.

In the event that a previously undisclosed potential competing interest for an author of a published paper comes to the attention of the editors and is subsequently confirmed with the authors, the undeclared interest will be published as an erratum in a future issue.

 

COI Policy: Reviewers and Editors

Reviewers must disclose to editors any conflicts of interest that could bias their opinions of the manuscript, and they should disqualify themselves from reviewing specific manuscripts if they believe it to be appropriate. As in the case of authors, silence on the part of reviewers concerning potential conflicts may mean either that such conflicts exist that they have failed to disclose, or that conflicts do not exist. Reviewers must therefore also be asked to state explicitly whether conflicts do or do not exist. Reviewers must not use knowledge of the work, before its publication, to further their own interests. COI for a given manuscript exists when a participant in the peer review and publication process – author, reviewer, and editor – has ties to activities that could inappropriately influence his or her judgment, regardless of whether judgment is, in fact, affected. Financial relationships with industry (for example, employment, consultancies, stock ownership, honoraria, expert testimony), either directly or through immediate family, are usually considered the most important conflicts of interest. However, conflicts can occur for other reasons, such as personal relationships, academic competition, and intellectual passion. External peer reviewers should disclose to editors any conflicts of interest that could bias their opinions of the manuscript and they should disqualify themselves from reviewing specific manuscripts if they believe it appropriate. The editors must be made aware of reviewers’ COI to interpret the reviews and judge for themselves whether the reviewer should be disqualified.” (From the International Committee of Medical Journal Editors Annals of Internal Medicine 118, (8) 646-647).
judge for themselves whether the reviewer should be disqualified.” (From the International Committee of Medical Journal Editors Annals of Internal Medicine 118, (8) 646-647).

 

Specific Policies

Submission by an editor. A paper submitted by an editor will be handled by one of the other editors who does not have a conflict with the review and who is not at the same institution as the submitting editor. The other editor will select referees and make all decisions on the paper.
Submission by author at same institution as one of the editors. A paper submitted by an author for which there is a potential conflict with who is at the same institution as one of the editors will be handled by one of the other editors. The other editor will select referees and make all decisions on the paper. Submission by family member of editor or by author whose relationship with editor might create the perception of bias. A paper submitted by a family member of one of the editors, or by an author whose relationship with one of the editors might create the perception of bias (e.g. in terms of close friendship or conflict/rivalry), will be handled by another editor. The other editor will select referees and make all decisions on the paper. If in doubt, the editors will consult with the Journal editor.

Potential COI for reviewers. The invitation letter to reviewers will include the following paragraph: ‘If you know or think you know the identity of the author, and if you feel there is any potential COI in your refereeing this paper because of your relationship with the author (e.g. in terms of close friendship or conflict/rivalry) or for any other reason, please declare it. By accepting this invitation, it is assumed there is no potential COI. Standard policy will be not to use a referee if a COI has been declared, but the editors may use their discretion after consulting with one another.

 

Revised Articles

Revised articles must be submitted again within 2 months, or else will be considered as rejected.

 

Galley Proofs

The corresponding Author will receive an e-mail with a pdf file of the galley proof. The galley proof can be downloaded as a PDF (portable document format) file. Acrobat Reader will be required in order to read this file. This will enable the file to be opened, read on screen and printed out in order for any corrections to be added. Excessive changes (i.e. over 100 characters) made by the Author to the proofs, excluding typesetting errors, will be charged separately. Changes to figures and tables have an extra cost. Please check carefully the galley proof (especially for what concerns name of Authors, affiliations and corresponding Authors) as after its approval no further change will be possible.

Before the publication, International Journal of Medical Device and Adjuvant Treatments sends the final galley proof in which only missed misstatements in the previous galley proof can be corrected.

 

Forthcoming Articles

Abstracts of the articles will appear 50-60 days after acceptance in the International Journal of Medical Device and Adjuvant Treatments Forthcoming section. Abstracts of the articles are, therefore, available as soon as they are ready, without having to wait for the next scheduled print issue. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They are, therefore, given a Digital Identifier Number (Ahead of print ID: IJMDAT), which allows the article to be cited and tracked before it is allocated to an issue. Forthcoming article is also a way to know if a paper has been accepted.